Worldwide Clinical Trials Executive and Leadership Team

Daniel Gizachew, the Chief Executive Officer at Worldwide Clinical Trials, directs the overarching corporate strategy and operational execution for the global Contract Research Organization. Gizachew guides the company's mission to provide high-performing preclinical and Phase I-IV clinical development services to the biotechnology and pharmaceutical sectors. This leadership role involves ensuring the seamless integration of bioanalytical sciences, early-phase research, and late-phase studies to support clients' drug development pipelines. Gizachew's focus extends to fostering innovation and maintaining the highest standards of quality across all service offerings, particularly within major therapeutic areas such as Cardiovascular, Metabolic, Neuroscience, Oncology, and Rare Diseases. The Chief Executive Officer's strategic vision propels Worldwide Clinical Trials' market position and commitment to advancing global health outcomes through rigorous scientific execution and client-centric solutions.

Kevin Gordon, the Interim Chief Financial Officer at Worldwide Clinical Trials, manages the organization's financial operations and strategic fiscal planning. Gordon oversees all aspects of financial reporting, budgeting, and resource allocation to support the company's global clinical development services. This critical role ensures financial stability and enables investment in key areas such as preclinical research, bioanalytical sciences, and Phase I-IV clinical trials. The Interim Chief Financial Officer's expertise is vital in navigating the financial complexities of the biotechnology and pharmaceutical industries, particularly concerning investments in therapeutic areas like Cardiovascular and Rare Diseases. Kevin Gordon's leadership provides essential financial oversight, driving sustainable growth and supporting the company's mission to deliver high-performing solutions to clients worldwide.

Keya Watkins, the President, Oncology at Worldwide Clinical Trials, directs the strategic growth and operational execution for the company's specialized oncology services. Watkins leads the development and delivery of comprehensive clinical trial solutions tailored to the unique needs of oncology research within the biotechnology and pharmaceutical sectors. This involves overseeing Phase I-IV clinical studies, bioanalytical sciences, and preclinical research specifically focused on cancer therapies. The President, Oncology's expertise ensures that clients receive cutting-edge support for their drug development pipelines in this critical therapeutic area. Keya Watkins's leadership drives innovation and excellence in oncology clinical development, reinforcing Worldwide Clinical Trials' position as a premier partner for advancing cancer treatments globally.

Alessandra Vignola, the President, Cardiovascular & Metabolic Business Unit at Worldwide Clinical Trials, spearheads the strategic direction and operational success of services focused on cardiovascular and metabolic diseases. Vignola guides the delivery of end-to-end clinical development solutions, encompassing preclinical research, bioanalytical sciences, and Phase I-IV clinical trials within these specific therapeutic domains. This leadership role ensures that clients in the biotechnology and pharmaceutical industries receive specialized expertise to advance treatments for conditions affecting the heart and metabolism. The President, Cardiovascular & Metabolic Business Unit's focus on innovation and quality drives the successful execution of complex clinical programs. Alessandra Vignola's commitment to excellence strengthens Worldwide Clinical Trials' capabilities in these vital areas, contributing significantly to global health advancements.

Deborah Jones-Hertzog, the Chief Information Officer at Worldwide Clinical Trials, architects and oversees the company's comprehensive technology infrastructure and digital strategy. Jones-Hertzog ensures that all information systems effectively support the delivery of preclinical and Phase I-IV clinical development services across global operations. This involves managing data security, implementing advanced analytics for clinical trial optimization, and driving digital transformation initiatives that enhance efficiency and client collaboration. The Chief Information Officer's responsibilities include selecting and deploying cutting-edge technologies that streamline bioanalytical sciences, early-phase research, and late-phase studies. Deborah Jones-Hertzog's leadership ensures robust IT capabilities, enabling Worldwide Clinical Trials to maintain its competitive edge in serving the biotechnology and pharmaceutical industries, particularly in therapeutic areas like Oncology and Neuroscience.

Lisa Skorets, the Chief Of Staff, GCD at Worldwide Clinical Trials, provides strategic operational support and drives key initiatives across the Global Clinical Development (GCD) function. Skorets facilitates cross-departmental collaboration, ensuring alignment between preclinical services, bioanalytical sciences, and Phase I-IV clinical studies. This role involves optimizing project execution, enhancing communication channels, and supporting the implementation of best practices within the organization. The Chief Of Staff, GCD's focus is on improving operational efficiency and effectiveness, directly contributing to the successful delivery of clinical development services for the biotechnology and pharmaceutical industries. Lisa Skorets's strategic contributions are instrumental in advancing the company's objectives in therapeutic areas such as Oncology and Neuroscience, reinforcing Worldwide Clinical Trials' commitment to excellence.

Joy Clark, the Chief People Officer at Worldwide Clinical Trials, leads the human capital strategy and organizational development initiatives. Clark oversees talent acquisition, employee engagement, and professional development programs designed to support the company's global workforce. This leadership position is crucial for attracting and retaining top talent essential for delivering high-performing preclinical and Phase I-IV clinical development services. The Chief People Officer's focus includes fostering a positive and inclusive company culture that aligns with Worldwide Clinical Trials' mission to serve the biotechnology and pharmaceutical industries. Joy Clark's dedication to people operations ensures that the organization has the skilled professionals needed to excel in critical therapeutic areas, including Cardiovascular, Metabolic, and Rare Diseases, driving overall success.